Physician profile
Michael Mosley
NPI 1841970530
$1,350.76
in general payments reported to CMS, 2019-2025
15 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $193 · 2024: $739 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,159 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,159.44 |
| Education | $191.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $488.80 | 2023-2025 | Tezspire, Airsupra, Symbicort |
| Sanofi-Aventis U.S. LLC | $173.94 | 2024 | |
| Genzyme Corporation | $144.64 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $133.49 | 2023-2025 | Dupixent |
| Glaxosmithkline, LLC. | $88.39 | 2024-2025 | Trelegy Ellipta, Nucala |
| Amgen INC. | $51.78 | 2024-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.54 | 2024-2025 | Ofev |
| Inspire Medical Systems, INC. | $46.31 | 2024-2025 | Inspire |
| Grifols USA, LLC | $33.15 | 2025 | Prolastin-C Liquid |
| Insmed, INC. | $32.21 | 2025 | Arikayce |
| Jazz Pharmaceuticals INC. | $30.71 | 2024 | |
| Lilly USA, LLC | $27.53 | 2025 | Zepbound |
| Philips North America LLC | $18.92 | 2024 | (Ak6) Vest Therapy |
| Gilead Sciences, INC. | $17.35 | 2024 | Veklury |
| Merck Sharp & Dohme LLC | $13.00 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mosley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.